With the high demand for Covid-19 testing, BioLife Sciences (OTCPK: BLFE) is pleased to announce the availability of the FebriDx® - an ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes.
TORONTO, ONTARIO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – With the high demand for Covid-19 testing, BioLife Sciences (OTCPK: BLFE) is pleased to announce the availability of the FebriDx® - an ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes.
Approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections, the test itself takes only 30 seconds and provides non-invasive test results for ARIs within ten (10) minutes.
The FebriDx®, available from BioLife Sciences, can be administered by trained professionals at places like: pharmacies, walk-in clinics, long-term care homes, workplaces, and doctors’ offices without the need for a laboratory to determine if someone is infected with the virus.
A healthcare worker performs a fingerstick blood sample during a patient’s initial workup. Upon generating the results, a treatment plan can be established during the patient’s initial visit or on-site, as opposed to waiting for 24 hours or longer. In the event of a positive COVID-19 test, rapid triaging can begin to successfully isolate patients and prevent further spread of the infection.
Currently, the majority of COVID-19 testing falls into two categories: polymerase chain reaction (PCR) technology and antigen assays, with the PCR test being the standard. Antigen assays are faster and cheaper than PCR tests; however, they are not as sensitive and as such, not as accurate.
The FebriDX® triage test does not replace the standard PCR test for COVID-19; however, what it does do is allow for immediate results for any bacterial and viral infections including, but not limited to, COVID-19. FebriDX® testing provides accurate results within ten minutes compared with 1.7 hours with PCR testing and 24 hours with laboratory testing. Additionally, the majority of tests are currently limited to the detection of a single group of pathogens (COVID-19) and cannot distinguish between alternative viral or bacterial infections which may have similar symptoms as COVID-19.
“Adding the FebriDX is a significant and timely addition to our product line,” said Mr. De Four, CEO of BioLife Sciences. “The FebriDx® test will enhance our goal of assisting the public in overcoming this pandemic and reducing the spread of COVID-19.” Under the terms of the agreement, BioLife will receive exclusive rights to market the FebriDX® through selected marketing channels to their client base.
For more information on the FebriDX® test, please visit:
https://www.biolifesciences.com/our-technology/febridx-covid-19-point-of-care-test/
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products, non-contact human temperature screening technology, and touchless vending/marketplaces. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
Disclaimer
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US: (775) 981-0270
Canada: (647) 558-6663
